AirXpanders Inc., a company developing innovative products addressing the breast and burn reconstruction markets, secured $10 million in Series D financing. Investors include Vivo Ventures, GBS Venture Partners, Heron Capital and Prolog Ventures.
This round will fund the ongoing U.S. Investigational Device Exemption (IDE) study for the AeroForm™ Patient Controlled Tissue Expander System.
Scott Dodson, CEO, said the company has already seen "great success" in the IDE study, with no adverse events reported to date.
See more from Medical Device Daily